Ligand Pharmaceuticals LGND Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's unrealized losses on investments (before tax)?
- Ligand Pharmaceuticals (LGND) reported unrealized losses on investments (before tax) of $3.92M in Q1 2026.
- How has Ligand Pharmaceuticals's unrealized losses on investments (before tax) changed year-over-year?
- Ligand Pharmaceuticals's unrealized losses on investments (before tax) increased by 111.4% year-over-year, from $1.85M to $3.92M.
- What is the long-term trend for Ligand Pharmaceuticals's unrealized losses on investments (before tax)?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's unrealized losses on investments (before tax) has grown at a 22.9% compound annual growth rate (CAGR), from $1.39M to $3.89M.